The European Commission has cleared the acquisition of Hospira by Pfizer in phase 1. The clearance is subject to the divestment of some sterile injectable drugs and one biosimilar pipeline.
A CRA team led by Raphaël De Coninck and including Elina Koustoumpardi, Roman Fischer, and Mikaël Hervé advised and provided economic support to Pfizer during the pre-notification and phase 1 proceedings in front of the European Commission.
For more details, please see the Commission’s press release.
The economics of 5G deployment in the “race” to 5G: The state of 5G in the US, South Korea, and other countries
As regulators in various countries consider when and how much spectrum to allocate for 5G services, valuable lessons can be learned from the experiences of 5G...